1-17 of 17
Douglas Gladstone
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-world experience with front-line metronomic low-dose weekly decitabine and venetoclax in elderly and/or frail patients with MDS or AML

Free
Adit Singhal, Pratik Shah, David Mueller, Lowena Tam, Stephanie Boisclair, Erin Jou, Bradley Goldberg, Jonathan Kolitz, Douglas Gladstone, David W. Chitty
Journal: Blood
Blood (2025) 146 (Supplement 1): 5186.
https://doi.org/10.1182/blood-2025-5186
Published: 2025
Journal Articles

17p cytogenetic changes in TP53-mutated AML

Free
David Mueller, Sharon Santhosh, Adit Singhal, David W. Chitty, Douglas Gladstone, Bradley Goldberg, Erin Jou, Jonathan Kolitz, Stephanie Boisclair
Journal: Blood
Blood (2025) 146 (Supplement 1): 3506.
https://doi.org/10.1182/blood-2025-3506
Published: 2025
Journal Articles

TP53-mutated AML and treatment outcomes in the era of hypomethylating agent/venetoclax therapy

Free
David Mueller, Sharon Santhosh, Adit Singhal, David W. Chitty, Douglas Gladstone, Bradley Goldberg, Erin Jou, Jonathan Kolitz, Stephanie Boisclair
Journal: Blood
Blood (2025) 146 (Supplement 1): 1705.
https://doi.org/10.1182/blood-2025-1705
Published: 2025
Journal Articles

Predictors of 90-day mortality in elderly and unfit AML patients treated with single-agent hypomethylating agents or in combination with venetoclax

Free
Melissa F. Neumann, Meredith Akerman, David Mueller, Nicholas Scelzi, Jasmine Cho, Aaron Goldstein, Shreya Sanghani, Stephanie Boisclair, Erin Jou, Bradley Goldberg, Jonathan Kolitz, Douglas Gladstone, Kanti Rai, David W. Chitty
Journal: Blood
Blood (2025) 146 (Supplement 1): 5166.
https://doi.org/10.1182/blood-2025-5166
Published: 2025
Journal Articles

Real-world outcome of low-frequency outpatient monitoring for venetoclax initiation in CLL: Single-center experience

Free
Monica Wallin, Sally Ko, Pratik Shah, Stephanie Boisclair, Douglas Gladstone, Teshmanie Rampersaud
Journal: Blood
Blood (2025) 146 (Supplement 1): 7919.
https://doi.org/10.1182/blood-2025-7919
Published: 2025
Journal Articles

ABC: Highly active and entirely calcineurin and m-TOR inhibitor-free gvhd prevention regimen

Free
A Samer Al-Homsi, Stephanie Boisclair, Jaime Andres Suarez-Londono, Kelli Cole, Omar Marzouk, Angie Fleury, Farzaneh Mashayekhi, Mariam Daghestani, Saud Khalaf, Ruthee Bayer, Douglas Gladstone, Maher Abdul Hay, Verona Abdelmeseh
Journal: Blood
Blood (2025) 146 (Supplement 1): 2469.
https://doi.org/10.1182/blood-2025-2469
Published: 2025
Journal Articles

The early discharge clinic: A safe and efficient model for intensive outpatient management of hematologic malignancies

Free
Christina Mallilo, Joo Yeon Seo, Brittany Mockler, Monica Wallin, Douglas Gladstone, Teshmanie Rampersaud
Journal: Blood
Blood (2025) 146 (Supplement 1): 7957.
https://doi.org/10.1182/blood-2025-7957
Published: 2025
Journal Articles

Cytomegalovirus Reactivation in Haploidentical Blood or Marrow Transplant (BMT) Using Post-Transplant Cyclophosphamide (PTCy) Is Associated with Higher Non-Relapse-Related Mortality, Despite Rarity of Disease

Free
Maria Veronica Dioverti, MD, Chiung-Yu Huang, PhD, Megan Morales, MD, Na Lu, Willa Cochran, NP, Douglas Gladstone, MD, Darin Ostrander, PhD, Robin Avery, MD, Richard J. Jones, MD, Richard F Ambinder, MD, Kieren Marr, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2096.
https://doi.org/10.1182/blood-2018-99-119603
Published: 2018
Journal Articles

A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)

Free
Stephen Ansell, MD PhD, Martin E Gutierrez, MD, Margaret A. Shipp, MD, Douglas Gladstone, MD, Alison Moskowitz, Ivan Borello, Mihaela Popa-Mckiver, Benedetto Farsaci, Lili Zhu, MS, Alexander M. Lesokhin, MD, Philippe Armand, MD PhD
Journal: Blood
Blood (2016) 128 (22): 183.
https://doi.org/10.1182/blood.V128.22.183.183
Published: 2016
Journal Articles

Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide.

Free
Laura K Schoch, MS, CRNP, Ivan Borrello, MD, Ephraim J. Fuchs, MD, Javier Bolanos-Meade, MD, Jeffrey Sean Huo, MD PhD, Ivana Gojo, MD, Nina Wagner-Johnston, MD, Gabrielle T Prince, MD, Shannon R. McCurdy, MD, B. Douglas Smith, MD, Amy E. DeZern, MD MHS, Margaret M. Showel, MD, David Loeb, MD PhD, Aziza T. Shad, MD, Richard J Jones, MD, Richard F. Ambinder, MD PhD, Douglas Gladstone, MD
Journal: Blood
Blood (2016) 128 (22): 4571.
https://doi.org/10.1182/blood.V128.22.4571.4571
Published: 2016
Journal Articles

Structural Chromosomal Changes Are Common Manifestation of FLT3 ITD Relapse and Presence of Chromosomal Progression Is Independent of Normal Karyotype at Diagnosis

Free
Melanie Rebechi, BS, Wesley Hand, B. Douglas Smith, MD, Ivana Gojo, MD, Margaret M. Showel, MD, Gabrielle T Prince, MD, Douglas Gladstone, MD, Shannon R. McCurdy, MD, Gabriel Ghiaur, MD PhD, Lukasz P Gondek, MD PhD, Amy E. DeZern, MD MHS, Mark J. Levis, MD PhD, Keith W. Pratz, MD
Journal: Blood
Blood (2016) 128 (22): 2868.
https://doi.org/10.1182/blood.V128.22.2868.2868
Published: 2016
Journal Articles

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias

Free
Ivana Gojo, MD, Jan H. Beumer, PharmD, PhD, Keith Pratz, MD, Jiuping Ji, Lihua Wang, PhD, Michelle A. Rudek, PharmD, PhD, Michael A. McDevitt, MD PhD, Maria R. Baer, MD, Amanda Blackford, ScM, B. Douglas Smith, MD, Steven D. Gore, MD, Hetty E. Carraway, MD MBA, Margaret M. Showel, MD, Mark J. Levis, MD PhD, Amy E. DeZern, MD MHS, Douglas Gladstone, MD, Tania Jain, MD, Jackie Greer, RN, Marie Pouquet, PharmD, Ali-walbi Ismail, PharmD, MS, James Herman, MD, Weijie Poh, PhD, Larry Karnitz, PhD, Scott H. Kaufmann, MD PhD, Alice Chen, MD, Judith E Karp, MD
Journal: Blood
Blood (2015) 126 (23): 1361.
https://doi.org/10.1182/blood.V126.23.1361.1361
Published: 2015
Journal Articles

Liberal Vs. Restrictive Transfusion Thresholds in Leukemia Patients: A Feasibility Pilot Study

Free
Amy E. DeZern, MD MHS, Katherine Williams, Karen E. King, MD, Wesley Hand, Mark J. Levis, MD PhD, B Doug Smith, MD, Ivana Gojo, MD, Keith W. Pratz, MD, Lukasz P Gondek, MD PhD, Gabrielle T. Prince, MD, Gabriel Ghiaur, MD PhD, Margaret M. Showel, MD, Douglas Gladstone, MD, Steve Frank, Paul M. Ness, MD
Journal: Blood
Blood (2015) 126 (23): 771.
https://doi.org/10.1182/blood.V126.23.771.771
Published: 2015
Journal Articles

Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia

Free
Douglas Gladstone, MD, Marc Andre, MD PhD, Jan Zaucha, MD PhD, Sarit Assouline, MD MSc, Naresh Bellam, MD MPH, Nicole Cascavilla, MD, Eric Jourdan, MD PhD, Amit Panwalkar, MD, Caterina Patti, MD, Clemens Schulte, MD, Francesco Zaja, MD, Trishna Goswami, MD, Nairouz Elgeioushi, MPH, Katie Streicher, PhD, Haifeng Bao, PhD, David Spaner, MD FRCPC, PhD
Journal: Blood
Blood (2014) 124 (21): 4472.
https://doi.org/10.1182/blood.V124.21.4472.4472
Published: 2014
Journal Articles

Outcomes Of Nonmyeloablative (NMA) Haploidentical Blood Or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy) For Lymphoma

Free
Yvette L. Kasamon, Javier Bolaños-Meade, Douglas Gladstone, Lode J. Swinnen, Jennifer A. Kanakry, Hua-Ling Tsai, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones, Richard F. Ambinder
Journal: Blood
Blood (2013) 122 (21): 2091.
https://doi.org/10.1182/blood.V122.21.2091.2091
Published: 2013
Journal Articles

Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy)

Free
Nilanjan Ghosh, MD, PhD, Xiaobu Ye, MD, MS, Javier Bolaños-Meade, MD, Ephraim J. Fuchs, Leo Luznik, Jennifer A. Kanakry, Robert A. Brodsky, MD, Mark Levis, MD, PhD, Lode J. Swinnen, Douglas Gladstone, MD, Yvette L. Kasamon, Richard F. Ambinder, Richard J. Jones, William Matsui, MD, Ivan M. Borrello, MD, Carol Ann Huff, M.D.
Journal: Blood
Blood (2013) 122 (21): 3407.
https://doi.org/10.1182/blood.V122.21.3407.3407
Published: 2013
Journal Articles

High Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis: 2-Year Follow-up (investigational new drug No. 65863).

Free
Douglas Gladstone, MD
Journal: Blood
Blood (2009) 114 (22): 4744.
https://doi.org/10.1182/blood.V114.22.4744.4744
Published: 2009